Anavex Reports That New Data Confirms Calcium Target Over-Expression May Be Involved in Causing Alzheimer’s Disease

Same Target Regulated Through Sigma-1 Receptor   New York — May 22, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, welcomes new data published in the current…